The ALLHAT study: Results and clinical implications

QJM: An International Journal of Medicine

Volumn 96, Issue 10, 2003, Pages 771-773

  Chrysant, S G ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; POTASSIUM SPARING DIURETIC AGENT; RESERPINE; SPIRONOLACTONE; TRIAMTERENE;

ADULT; AGED; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; PRIORITY JOURNAL; STROKE;

EID: 0141960096     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg123     Document Type: Article

References (23)

1. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group: Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.
2. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967-75.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7 Report). JAMA 2003; 289:2560-72.
4. Chrysant SG, Danisa K, Ken DC, et al. Racial differences in pressure, volume and renin inter-relationships in essential hypertension. Hypertension 1979; 1:136-41.
5. Chrysant SG, Weder AB, McCarron DA, et al. for the MIST II Trial Investigators: Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. Am J Hypertens 2000; 13:1180-8.
6. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-92.
7. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril hydrochlorothiazide combination. A large multicenter study. Arch Intern Med 1994; 154:737-43.
8. Staessen JA, Wang JG, Thij SL. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15:859-935.
9. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355:1955-64.
10. Chrysant SG, Brown JL, Hagstrom D. Antihypertensive and metabolic effects of hydrochlorothiazide and timolol. J Clin Pharmacol 1983; 23:147-54.
11. Holland OB, Nixon JU, Kuhnert I. Diuretic induced ventricular activity. Am J Med 1981; 70:762-8.
12. Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med 1984; 80(4A):28-32.
13. Papademetriou V, Fletcher R, Khatri LM, et al. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med 1988; 148:1272-6.
14. Chyrysant SG, Neller GF, Dillard BL, Frohlich ED. Effect of diuretics on lipid metabolism in patients with essential hypertension. Angiology 1976; 27:707-11.
15. Chrysant SG. fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998; 7:370-6.
16. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrocholorothiazide, given alone and in low and high-dose combinations on blood pressure in patients with hypertension. Arch Fam Med 1996; 5:17-24.
17. Chrysant SG, Wombolt DG, Feliciano N, Zheng H. Long-term efficacy, safety and tolerability of valsartan and hydrocholorothiazide in patients with essential hypertension. Curr Ther Res 1998; 59:762-72.
18. Chrysant SG, Chappel C, Larnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992; 32:61-5.
19. Frishman WH, Ram CVS, McMahon FG, Chrysant SG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel group study. J Clin Pharmacol 1995; 35:1060-6.
20. Chrysant SG, Gavras H, Niederman AL, et al. Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. J Clin Pharmacol 1997; 37:810-15.
21. Chrysant SG. Calcium channel blockers are effective and safe antihypertensive drugs. Cardiovasc Rev Rep 2001; 22:189-91.
22. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003; 361:1629-41.
23. Laragh JH. Abstract, closing summary, and table of contents for Laragh's 2 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens 2001; 14:1173-7.